Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;31(42):7030-7042.
doi: 10.2174/0109298673286355231222054226.

Integrating Single-cell and Bulk RNA-seq to Construct a Metastasis-related Model for Evaluating Immunotherapy and Chemotherapy in Uveal Melanoma

Affiliations

Integrating Single-cell and Bulk RNA-seq to Construct a Metastasis-related Model for Evaluating Immunotherapy and Chemotherapy in Uveal Melanoma

Yue Du et al. Curr Med Chem. 2024.

Abstract

Background: Metastasis is a major cause of death in UM, highlighting the need to use highly specific and sensitive prognostic markers to identify patients with a risk of developing metastasis.

Aims: The aim of this study was to improve the current precision treatment for patients with metastatic uveal melanoma (UM).

Objective: The objective of this work was to investigate the heterogeneity between primary human UM and metastatic UM at the single-cell level and to discover potential molecules regulating UM metastasis.

Methods: Seurat R toolkit was employed to analyze single-cell sequencing data of UM and to identify differentially expressed genes (DEGs) between primary and metastatic UM. Least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were performed on the DEGs from the bulk RNA-seq cohort to develop a prognostic model. Based on the model, patients were divided into high and low groups. The correlations among the risk score, immune indicators, immune checkpoint blockade (ICB) therapy, and anti-tumor drug therapy were analyzed.

Results: Cell types in primary UM and metastatic UM tumors include B/plasma cells, endothelial cells, melanocytes, monocytes/macrophages, photoreceptor cells, and T cells. Among 157 DEGs between the two tumor types, S100A4, PDE4B, CHCHD10, NSG1, and C4orf48 were selected to construct a prognostic model. The model could accurately and independently predict response to ICB treatment and sensitivity to antineoplastic drugs for UM patients as well as their immune infiltration levels, risk of death, and metastasis possibility.

Conclusions: This study analyzed the tumor ecosystem of primary and metastatic UM, providing a metastasis-related model that could be used to evaluate the prognosis, risk of metastasis, immunotherapy, and efficacy of antineoplastic drug treatment of UM.

Keywords: Uveal melanoma; anti-tumor.; antineoplastic drugs; immunotherapy; metastasis; tumor microenvironment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Smit K.N.; Jager M.J.; de Klein A.; Kiliҫ E.; Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res 2020,75,100800 - DOI - PubMed
    1. Sajan A.; Fordyce S.; Sideris A.; Liou C.; Toor Z.; Filtes J.; Krishnasamy V.; Ahmad N.; Reis S.; Brejt S.; Baig A.; Khan S.; Caplan M.; Sperling D.; Weintraub J.; Minimally invasive treatment options for hepatic uveal melanoma metastases. Diagnostics 2023,13(11),1836 - DOI - PubMed
    1. Banou L.; Tsani Z.; Arvanitogiannis K.; Pavlaki M.; Dastiridou A.; Androudi S.; Radiotherapy in uveal melanoma: A review of ocular complications. Curr Oncol 2023,30(7),6374-6396 - DOI - PubMed
    1. Costanzo R.; Parmar V.; Marrone S.; Gerardo I.D.; Federico N.G.; Emmanuele U.G.; Scalia G.; Differential diagnosis between primary intracranial melanoma and cerebral cavernoma in Crohn’s disease: A case report and literature review. Oncologie 2022,24(4),937-942 - DOI
    1. Chattopadhyay C.; Kim D.W.; Gombos D.S.; Oba J.; Qin Y.; Williams M.D.; Esmaeli B.; Grimm E.A.; Wargo J.A.; Woodman S.E.; Patel S.P.; Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 2016,122(15),2299-2312 - DOI - PubMed

Substances

LinkOut - more resources